NewAmsterdam Pharma

NAMS

Market cap $4.07B

Overview Fund Trends Analyst Outlook Journalist POV

36.14 USD

+0.10

0.28%

At close Updated Oct 28, 4:00 PM EDT

Pre-market

After hours

36.10

--0.04

0.11%

1 day

0.28%

5 days

0.17%

1 month

31.32%

3 months

54.31%

6 months

102.69%

Year to date

39.21%

1 year

88.92%

5 years

249.18%

10 years

249.18%

About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Employees: 77

Healthcare Biotechnology